The National Institutes of Health (NIH) will test whether remdesivir and aviptadil acetate are safe and effective when used together or alone to treat hospitalized COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS). The Phase 3 clinical trial, part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, recently began enrolling 40 patients at U.S. sites. According to Gary Gibbons, MD, director of NIH’s National Heart, Lung and Blood Institute, the trial also could shed light on the repair of damaged lungs following ARDS. (NIH news release, 4/22/21)
